- Healthy African-American male and/or female subjects of non-childbearing potential
between the ages of 18 and 55 years, inclusive.
- Pregnant females; breastfeeding females; and females of childbearing potential. Males
who are unwilling or unable to use 2 highly effective method of contraception for the
duration of the study starting at least 14 days prior to the first dose of
investigational product and for at least 28 days after the last dose of
- Non African-American.
- Evidence or history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
allergic disease (including drug allergies, but excluding untreated,
asymptomatic,seasonal allergies at the time of dosing).